Curadel Pharma is an audacious innovator aiming to prevent tumor resistance via disruptive zwitterionic radiopharma technology. Its novel, pan-tumor platform prevents tumor regrowth and resistance while eliminating collateral damage to healthy tissues. Curadel’s lead candidate, CPI-003, represents a...See more
Headquarters:
Company Type:
SME
Company size:
11-50 Employees
Year Founded:
2012 (13 years)
Address:
null
LOW
spending power
